The Ritedose Corp

11/16/2026 | Press release | Distributed by Public on 11/16/2026 17:51

Why Single-Use Dosing in Pharmaceutical Manufacturing Matters for Patient Safety

Many drugs rely on reusable, resealable vials to accommodate multiple doses in a single container. These can be appropriate for certain oral medications and other drug formulations. However, ophthalmic and respiratory therapies often require delivery systems designed to maintain sterility and support precise dosing.

As the largest U.S. contract development and manufacturing organization (CDMO) specializing in sterile Blow-Fill-Seal (BFS) technology, Ritedose incorporates this specialized BFS process to create sterile single-use ampules-helping pharmaceutical partners address critical product-quality requirements while prioritizing patient safety. These vials are designed to deliver a precise amount of medication for an individual administration for the prescribed dosage.

Single-Use, BFS, cGMP in Concert

When using BFS technology under cGMP, drugs are filled in single-use vials in a continuous process that minimizes exposure to potential contaminants. This advanced manufacturing approach supports product integrity and patient safety. BFS is a key technology in Ritedose's manufacturing approach and is considered the gold standard of sterile processing.

The process begins by forming a sterile zone surrounded by a plastic parison. Inside the sterile zone are sterilized filling needles and sterile air. Each dosage of medication is formed, filled and sealed in one continuous, closed operation. This manufacturing approach drastically reduces opportunities for contamination during production while also supporting the consistent quality and container integrity of sterile ophthalmic and respiratory medications.

BFS technology creates a sterile product but maintaining that sterility after the container is opened depends on proper handling by the patient. Once opened, the contents may be exposed to potential sources of contamination, making it essential to follow product instructions and use the medication as directed.

To minimize this risk, the Food and Drug Administration (FDA) advised that opened unit-dose medications be used immediately and any remaining contents discarded, even if medication remains in the container. Despite this guidance, some manufacturers and drug developers have advocated for reusable, reclosable containers for unit-dose medications. At Ritedose, we believe patient education is essential to communicating the risks of using single-use vials for multiple doses and reinforcing the importance of following recommended handling and use instructions.

What are the Risks?

Research has shown that improper reuse of single-dose vials remains a concern in healthcare settings. In a 2010 survey of more than 5,400 healthcare professionals, 6% of respondents reported sometimes or always using single-dose or single-use vials for more than one patient. Although this practice may appear to reduce costs or medication waste, it creates opportunities for cross-contamination and puts patient safety at risk.

Research has also demonstrated the potential for contamination in ophthalmic medications. A 2021 German study examined 245 multidose eye-drop bottles collected in a controlled operating-room environment. Researchers found contamination on the dropper tips of five bottles, representing 2% of the samples. All five contained gram-positive bacteria, primarily organisms associated with normal skin flora. Although the contamination rate was relatively low, the researchers emphasized that contamination remained possible even in a carefully controlled clinical environment.

Further Embracing Single-Use

The pharmaceutical industry continues to explore packaging and filling innovations that improve medication safety, usability and dosing accuracy. Single-use vials offer several advantages, including protecting medication integrity before opening, delivering a precise amount of medication and eliminating the need for patients to measure individual doses from a larger container.

These benefits are particularly important for ophthalmic and respiratory medications, where proper administration and product handling play an important role in treatment. Single-use dosing options also provide an alternative for preservative-free formulations, helping manufacturers address concerns about the potential effects of certain preservatives.

As pharmaceutical manufacturers continue to prioritize product quality and patient experience, demand for single-use vials is expected to grow. Ritedose is helping meet that demand through its expertise in sterile BFS manufacturing, producing single-use ophthalmic and respiratory medications designed to support precise dosing and product quality.

Single-use dosing solutions play an important role in protecting medication quality, supporting precise dosing and helping reduce opportunities for contamination. When combined with sterile BFS manufacturing and cGMP practices, it provides pharmaceutical manufacturers with a proven approach to producing sterile ophthalmic and respiratory medications.

At Ritedose, patient safety begins long before a medication reaches the person who needs it. It starts with the sterile manufacturing processes, packaging technologies and quality standards that help protect every dose. That's why we continue to invest in sterile BFS technology, as well as champion and educate around the proper use of single-use medications. Because at Ritedose, The Patient is Our Why.

About The Ritedose Corporation

Ritedose is the largest sterile contract development manufacturing organization (CDMO) in the US specializing in sterile Blow Fill Seal (BFS) technology that ensures sterile, consistent, and safe unit dose delivery. The Company's process guides the development of molecules from clinical trials to commercialization of branded and generic inhalation and ophthalmic medications. With a focus on quality, innovation, and customer satisfaction, Ritedose partners with leading pharmaceutical companies to deliver safe, effective, and reliable medications that improve patient outcomes. For more information about Ritedose and its services: visit Ritedose.com.

The Ritedose Corp published this content on November 16, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 16, 2026 at 23:51 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]